We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
124 hedge funds and large institutions have $104M invested in Esperion Therapeutics in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 61 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $1.41M
12.65% less ownership
Funds ownership: 91.19% → 78.54% (-13%)
19% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 37
20% less capital invested
Capital invested by funds: $129M → $104M (-$25.5M)
24% less funds holding
Funds holding: 164 → 124 (-40)
62% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 61
Holders
124
Holders Change
-40
Holders Change %
-24.39%
% of All Funds
1.95%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
30
Reduced
37
Closed
61
Calls
$2.51M
Puts
$1.41M
Net Calls
+$1.1M
Net Calls Change
-$1.81M
Top Buyers
Top Sellers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.64M |
| 2 |
BlackRock
New York
|
-$4.91M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.24M |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.64M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.5M |